# DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

> **NCT05966064** · PHASE4 · RECRUITING · sponsor: **Natasha Appelman-Dijkstra** · enrollment: 82 (estimated)

## Conditions studied

- Fibrous Dysplasia
- McCune Albright Syndrome

## Interventions

- **DRUG:** Denosumab 120 Mg/1.7 Ml Inj
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05966064
- **Lead sponsor:** Natasha Appelman-Dijkstra
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966064, "DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05966064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*